New Phase II data show interferon-free combinations of HCV therapeutics being developed by Abbott Laboratories (NYSE:ABT) and Bristol-Myers Squibb Co. (NYSE:BMY) could produce sustained virologic response (SVR) rates >90% in patients infected with HCV genotype 1 without the use of a nucleotide-based NS5B inhibitor.

The best data previously reported were from Gilead Sciences Inc. (NASDAQ:GILD) and BMS, which announced Phase II results in April showing 100% sustained virologic response (SVR) in patients receiving the nucleotide NS5B inhibitor sofosbuvir (GS-7977) and the NS5A inhibitor daclatasvir. Gilead declined to advance the combination into Phase III. The biotech is instead developing sofosbuvir with its own NS5A inhibitor, GS-5855. Preliminary results from that combination are expected to be presented at the American Association for the Study of Liver Diseases (AASLD) meeting next month.